BioStock Studio: Immunicum och DCprime går samman inom immunonkologi Investments om att förvärva alla aktier i DCprime, ett holländskt

2021-01-27

Genom transaktionen förvärvar Immunicum samtliga utestående aktier i DCprime genom en apportemission till DCprimes största aktieägare Van Herk Investments B.V. Press Release21 December 2020Immunicum AB (publ) Completes Business Combination with DCprimeImmunicum AB (publ; IMMU.ST) ("Immunicum" or the "Company") today completed the business combination with DCPrime BV, a Dutch clinical stage company developing cancer relapse vaccines aimed to reduce tumor recurrence, via the acquisition of all shares in DCPrime BV. In accordance with … 2021-03-16 Immunicum AB (publ; IMMU.ST) ("Immunicum" or the "Company") today completed the business combination with DCPrime BV, a Dutch clinical stage company developing cancer relapse vaccines aimed to 2020-12-08 Immunicum AB (publ; IMMU.ST) announced today the establishment of an updated executive management team following the initial integration period of the business combination with DCprime that was completed in December 2020.. In the new composition, the executive management team consists of Erik Manting, Ph.D., as Chief Executive Officer (CEO), Lotta Ferm as Interim Chief Financial Officer … On 18 November, Immunicum announced that it had agreed to acquire biotech company DCprime by issuing 73.9k new shares or 44% of the enlarged capital. Based in the Netherlands, the privately owned biotech is developing a novel class of allogeneic dendritic cell-based cancer vaccines. The most advanced programme is in AML (Phase II) with interim data presented at the ASH conference on 5–8 About DCprime DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent diseaserecurrence.

Immunicum dcprime

Aktieöverlåtelseavtalet har ingåtts med Van Herk Investments B.V. och Van Herk Royalty B.V., vilket är ett bolag inom Van Herk koncernen och den nuvarande aktieägaren av aktierna i DCprime, har anslutit till avtalet. Pressmeddelande. 18 november 2020. Immunicum och DCprime går samman för att skapa ett ledande bolag inom cellbaserade immunterapier-- Kombinationen av bolagens unika angreppssätt och expertis skapar betydande synergier inom allogen dendritcellsbiologi -- December 5, 2019 DCprime Receives US FDA Orphan Drug Designation for DCP-001 in Acute Myeloid Leukemia 6 May 2020 Immunicum AB (publ) Receives Regenerative Medicine Advanced Therapy Designation from FDA for Ilixadencel in Kidney Cancer 7 December 2020 Immunicum AB (publ) Receives FDA Fast Track Designation for Ilixadencel in Gastrointestinal Stromal Tumors (GIST) 31 December 2020 Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Careers. We are a clinical-stage biopharmaceutical company developing cell-based immunotherapies built on decades of experience.

utvecklad av Immunicum har genom nyckelrekryteringar och att vi numera är noterade på börsens BioStock Studio: Immunicum och DCprime

Publicerad: 2020-11-18 (GlobeNewswire) Immunicum AB and DCprime Combine Forces to Establish Leader in Cell-Based Cancer Immunotherapies. Publicerad: 2020-11-18 (GlobeNewswire) DCprime's product is a whole-cell-based vaccine addressing blood cancers with a high risk of relapse. DCprime is pursuing similar vaccination approaches for solid tumors.

Immunicum – koncernen * Den 21 december 2020 förvärvade Immunicum AB DCprime BV. Transaktionen ledde till att det förvärvade bolaget DCprime BV:s tidigare ägare, utifrån ett redovisningsperspektiv, erhöll bestämmande inflytandet över det förvärvande bolaget Immunicum. Förvärvet redovisas därför som ett omvänt förvärv.

In the new composition, the executive management team consists of Erik Manting, Ph.D., as Chief Executive Officer (CEO), Lotta Ferm as Interim Chief Financial Officer (CFO), Alex Karlsson-Parra Den 18 november offentliggjorde Immunicum att bolaget ingått ett bindande avtal med Van Herk Investments BV om att förvärva samtliga aktier i DCprime BV för att skapa ett ledande bolag inom cellbaserade immunterapier. Vid extra bolagsstämman den 18 december godkändes styrelsens beslut om riktad nyemission om aktier till Van Herk Investments. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com. ABOUT DCPRIME. DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent disease recurrence. As such, joining forces with DCprime, an innovative company with extensive expertise in allogeneic dendritic cell biology, stands as an exciting opportunity with great potential for Immunicum that will build additional value for the Company, our shareholders and future patients,” stated Sven Rohmann, MD, Ph.D., Chief Executive Officer of Immunicum.

2020-12-07 · DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after standard of care therapy to delay or prevent disease recurrence. Relapse vaccines are aimed at improving survival by putting the patient’s immune system back in control while tumor burden is low, and the immune system is in relatively good shape.
Social integration betydelse

Company Profile; Management Team; Board of Directors; Scientific Advisory Board; Careers; Contact; Technology. Immunicum’s Approach; Ilixadencel; Development Programs; Publications; Pipeline. Pipeline; Clinical Trial Information; Expanded Access / Compassionate Use Policy; Partnering; Investors.

Bolaget driver huvudsakligen utveckling inom immunterapi med fokus på behandling av diverse allvarliga tumörer. Exempel på sjukdomar som produkter vidare används mot innefattar njur- och levercancer.
Översätta svenska betyg till engelska

Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors.

Immunicum has entered into an agreement with Van Herk Investments B.V. to acquire all of the shares in DCprime B.V., a Dutch clinical stage company developing cancer relapse vaccines aimed to reduce tumor recurrence. On 18 November 2020, Immunicum announced that it had entered into an agreement with Van Herk Investments BV to acquire all shares in DCPrime BV (the “Transaction”) through an issue in kind of Immunicum AB (publ; IMMU.ST) ("Immunicum" or the "Company") today completed the business combination with DCPrime BV, a Dutch clinical stage company developing cancer relapse vaccines aimed to Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.comAbout DCprimeDCprime is the front-runner in the field of relapse vaccines, a new class of Press Release 18 November 2020Immunicum AB and DCprime Combine Forces to Establish Leader in Cell-Based Cancer Immunotherapies\-- Synergistic combination of each company’s unique approach and joint Immunicum will further propose to the EGM the approval of a mandate for the Board of Directors to resolve to issue shares in a directed issue of up to 20 percent of the outstanding shares after the Transaction to facilitate financing activities.Comments from Immunicum and DCprime “As announced in the recent corporate and clinical update from Immunicum AB (publ; IMMU.ST) announced today the establishment of an updated executive management team following the initial integration period of the business combination with DCprime that was DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent disease recurrence. DCprime’s product is a whole-cell-based vaccine addressing blood cancers with a high risk of relapse.

38,24 euro

Immunicum has announced that Jeroen Rovers, M.D., Ph.D., has been appointed to the position of Chief Medical Officer (CMO). Rovers transitions from his role as Managing Director of DCprime and continues to serve on Immunicum’s management team.

DCprime, now part of Immunicum AB (IMMU), continues to grow at our core R&D facility in Leiden, The Netherlands. To support the further development of the Forskningsbolaget Immunicums vd Carols de Sousa med Carlos de Sousa om BioStock Studio: Immunicum och DCprime går Köp aktien hos I veckans avsnitt gästas vi av Sven Rohmann, vd för Immunicum och Erik Manting, vd för Dcprime. I programmet tar vi upp den föreslagna sammanslagningen av Jag ser fram emot att leda Immunicum nr bolaget nu tar nsta steg i frndringsresan efter sammanslagningen med DCprime. Efter samgendet r Immunicum köper och går samman med DCprime — Pål Brunnström sin avhandling med titeln ” Ägare. Klass och kapital. Immunicum offentliggörandet av förvärvet, Bolagets aktiekurs har fallit med 9 procent.7. 1 Immunicum och DCprime går samman för att skapa ett ledande Immunonkologibolaget Immunicums börsvärde tog ett rejält kliv uppåt på -studio-immunicum-och-dcprime-gar-samman-inom-immunonkologi/.